Cisplatin boosts the immunogenicity of the tumor, i.e., by increasing the expression of Major Histocompatibility Complex class I (MHC I) at tumor cell surface, thus facilitating recognition by activated CD8+ T lymphocyte. The gene discussed is CD8A; the disease is neoplasm.